Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033)

CONCLUSION: In Japanese infants, a four-dose series of V114 was generally well tolerated. Compared with PCV13, V114 provided non-inferior immune responses to the 13 shared serotypes and higher immune responses to serotype 22F and 33F post-primary series.TRIAL REGISTRATION: ClinicalTrials.gov: NCT04384107; EudraCT 2019-003644-68.PMID:37344262 | DOI:10.1016/j.vaccine.2023.05.064

Source: Vaccine - June 21, 2023 Category: Allergy & Immunology Authors: Hiroko Suzuki Hidetoshi Fujita Kazuyuki Iwai Haruo Kuroki Kazuhiko Taniyama Toshiyuki Shizuya Hiroyuki Kishino Rie Igarashi Masayoshi Shirakawa Miyuki Sawata Source Type: research